ReviewBiophysical reviews2026
AGGRESCAN and its evolution: A two-decade perspective on protein aggregation prediction.
Review in Biophysical reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein aggregation is a widespread phenomenon with profound biological, biomedical, and biotechnological implications. In human disease, aberrant protein self-assembly is a hallmark of numerous neurodegenerative disorders, whereas in the biopharmaceutical industry, aggregation complicates the production, stability, and formulation of therapeutic proteins. The Aggrescan platform was one of the first empirically based tools designed to predict aggregation-prone regions (APRs) within protein sequences. It has since expanded to incorporate three-dimensional structural contexts and environmental conditions. This review provides a comprehensive overview of the development, application, and impact of the Aggrescan family of tools, which includes AGGRESCAN, Aggrescan3D, and the recent Aggrescan4D. We examine the algorithmic foundations, empirical validation, and key use cases spanning fields from biotechnology to biomedical research. Additionally, we describe how the recent integration of AlphaFold models has enabled proteome-scale exploration of aggregation determinants. This review highlights how Aggrescan has evolved alongside with advances in the field, becoming a reliable and accessible tool for studying and redesigning protein aggregation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.